Wolff, A.C., Hammond, M.E. and Schwartz, J.N. (2007) American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Journal of Clinical Oncology, 25, 118-145.
https://doi.org/10.1200/JCO.2006.09.2775

has been cited by the following article:

• TITLE: TRAIL and TRAIL Receptors as Prognostic Markers in Breast Cancer Patients

  AUTHORS: Fawziya A. R. Ibrahim, Marwa S. Abouelenein, Ola S. A. Sakr, Sanaa S. Ahmed, Ebtisam R. Zaher, Shaymaa E. el Feky

  KEYWORDS: Breast Cancer, Apoptosis, TRAIL, Prognosis

  JOURNAL NAME: American Journal of Molecular Biology, Vol.9 No.4, September 23, 2019

  ABSTRACT: Background: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a key player in the extrinsic pathway of apoptosis; it selectively damages cancer cells through binding to its surface receptors, however, cancers can escape this pathway through expression of dysfunctional decoy receptors. Purpose: The present study directed mainly to elucidate the serum TRAIL levels in breast cancer patients and to explore the variation in gene expression of TRAIL death and decoy receptors in breast cancer tissues, and to explore their role as prognostic markers in breast cancer as well as to detect their correlation with Patients’ Clinical Characteristics. Subjects and Methods: TRAIL levels were assayed in the sera of 124 breast cancer patients and 150 healthy females. Moreover, the expression of TRAIL death and decoy receptors was determined in both malignant and adjacent normal breast tissues collected from patients. ER, PR and Her-2 expression in breast cancer tissue were performed using immunohistochemical method. Apoptotic index (AI) was analyzed using H&E stain under light microscopy. Results: Serum levels of TRAIL in breast cancer patients were significantly lower than controls (P Conclusions: The expression of both DR4 and DR5 is required for TRAIL-induced apoptosis in breast cancer tissues; in addition, serum TRAIL and profiling of TRAIL receptors expression may serve as prognostic markers in breast cancer patients.